4-(propylamino)butan-1-ol | 42042-70-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-(propylamino)butan-1-ol
• 英文别名: 4-(Propylamino)-1-butanol
• CAS: 42042-70-6
• 化学式: C₇H₁₇NO
• 分子量: 131.218
• InChiKey: MGRXNAJUQKEJJB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(propylamino)butan-1-ol 在 钯 氢气 作用下， 以 乙醇 为溶剂， 生成 3.4.5-Trimethoxy-benzoesaeure-<4--butylester>
  参考文献：
  名称：

  Kralt,T. et al., Recueil des Travaux Chimiques des Pays-Bas, 1961, vol. 80, p. 330 - 357

  摘要：

  DOI：
• 作为产物：
  描述：

  2,3-二氢呋喃 、 正丙胺 生成 4-(propylamino)butan-1-ol
  参考文献：
  名称：

  Hoffman, Robert V.; Salvador, James M., Journal of the Chemical Society. Perkin transactions I, 1989, p. 1375 - 1380

  摘要：

  DOI：

文献信息

• [EN] MACROCYCLIC BETA-SECRETASE INHIBITORS<br/>[FR] INHIBITEURS DE BÊTA-SECRÉTASE MACROCYCLIQUES
  申请人：SCHERING CORP

  公开号：WO2006014944A1

  公开（公告）日：2006-02-09

  Disclosed are novel compounds of the formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, n and X are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula (I). Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are methods of treating a cognitive or neurodegenerative disease comprising administering to a patient I need of such treatment a combination of at least one compound of formula (I) and at least one compound selected from the group consisting of -secretase inhibitors other than those of formula (I), HMG-CoA reductase inhibitors, gamma-secretase inhibitors, non-steroidal anti-inflammatory agents, N-methyl-D-aspartate receptor antagonists, cholinesterase inhibitors and anti-amyloid antibodies.

  揭示了以下式（I）的新化合物：或其药学上可接受的盐或溶剂，其中R1、R2、R3、n和X如规范中所定义。还揭示了包括式（I）化合物的药物组合物。还揭示了治疗认知或神经退行性疾病如阿尔茨海默病的方法。还揭示了治疗认知或神经退行性疾病的方法，包括向需要此类治疗的患者施用至少一种式（I）化合物和选自-分泌酶抑制剂（不包括式（I）的那些）、HMG-CoA还原酶抑制剂、γ-分泌酶抑制剂、非甾体抗炎药、N-甲基-D-天冬氨酸受体拮抗剂、胆碱酯酶抑制剂和抗淀粉样抗体的化合物组合物的方法。
• COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES
  申请人：Arvinas, Inc.

  公开号：US20180179183A1

  公开（公告）日：2018-06-28

  The present disclosure relates to bifunctional compounds, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A-RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为快速加速纤维肉瘤（RAF，如c-RAF、A-RAF和/或B-RAF；目标蛋白）的调节剂而发挥作用。具体而言，本公开涉及含有一端为Von Hippel-Lindau、cereblon、凋亡抑制蛋白或鼠双分子同源物2配体的双功能化合物，该配体与相应的E3泛素连接酶结合，并且另一端含有结合目标蛋白RAF的基团，使得目标蛋白与泛素连接酶靠近，以实现目标蛋白的降解（和抑制）。本公开展示了与目标蛋白的降解/抑制相关的广泛药理活性范围。本公开的化合物和组合物用于治疗或预防由目标蛋白的聚集或积累，或目标蛋白的构成性激活导致的疾病或紊乱。
• Syntheses of N-alkyl-N-(hydroxy- or oxo-alkyl)nitrosamines related to N-butyl-N-(4-hydroxybutyl)nitroamine, a potent bladder carcinogen.
  作者：MASASHI OKADA、EMAKO SUZUKI、MINORU IIYOSHI

  DOI：10.1248/cpb.26.3891

  日期：——

  Nineteen N-alkyl-N-(hydroxy- or oxo-alkyl) nitrosamines structurally related to N-butyl-N-(4-hydroxybutyl) nitrosamine, a potent bladder carcinogen, were synthesized for the purpose of investigating their carcinogenic effects in rats. They are N-alkyl-N-(4-hydroxybutyl) nitrosamines, N-alkyl-(3-hydroxypropyl)-nitrosamines, N-alkyl-N-(2-hydroxyalkyl) nitrosamines, and N-alkyl-N-(2- or 3-oxoalkyl) nitrosamines. They were mostly prepared by the nitrosation of the corresponding N-alkyl-N-(hydroxyalkyl) amines. The nitrosamines with an oxo group were prepared by chromium trioxide oxidation of the corresponding N-alkyl-N-(hydroxyalkyl) nitrosamines with a secondary hydroxyl group.

  为研究其在大鼠体内的致癌效应，合成了19种与N-丁基-N-(4-羟基丁基)亚硝胺（一种强效膀胱致癌物）结构相关的N-烷基-N-(羟基或氧代烷基)亚硝胺。这些亚硝胺包括N-烷基-N-(4-羟基丁基)亚硝胺、N-烷基-N-(3-羟基丙基)亚硝胺、N-烷基-N-(2-羟基烷基)亚硝胺以及N-烷基-N-(2-或3-氧代烷基)亚硝胺。它们主要通过相应N-烷基-N-(羟基烷基)胺的亚硝化反应制备。含有氧代基团的亚硝胺则通过铬酐氧化相应的具有次级羟基的N-烷基-N-(羟基烷基)亚硝胺制备。
• COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20210147383A1

  公开（公告）日：2021-05-20

  Disclosed are compounds of Formula (I): or a salt thereof, wherein: Z is CR 6 R 6 or C═O; Ring A is: and R 1 , R 2 , R 3 , R 4 , R 5 , m, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

  公开的化合物为Formula (I)的化合物或其盐，其中：Z为CR6R6或C═O；环A为：而R1、R2、R3、R4、R5、m和n在此处有定义。还公开了使用这些化合物抑制Helios蛋白的方法，以及包含这些化合物的药物组合物。这些化合物在治疗病毒感染和增生性疾病（如癌症）方面非常有用。
• Substituierte Aminoalkanolphospholipide und Verfahren zu ihrer Herstellung
  申请人：A. Nattermann & Cie. GmbH

  公开号：EP0107120A1

  公开（公告）日：1984-05-02

  Die Erfindung betrifft neue substituierte Aminoalkanolphospholipide der allgemeinen Formel 1 und Verfahren zu ihrer Herstellung. Die Verbindungen zeigen starke biologische Aktivität und können z.B. in Arzneimitteln und im Pflanzenschutz eingesetzt werden. Sie besitzen z.B. blutdrucksenkende, entzündungshemmende. tumorhemmende und antiatherosklerotische Eigenschaften.

  本发明涉及通式 1 的新型取代氨基烷醇磷脂及其制备工艺。 及其制备工艺。这些化合物具有很强的生物活性，可用于制药和植物保护等领域。例如，它们具有抗高血压、抗炎、抗肿瘤和抗动脉粥样硬化的特性。